Literature DB >> 18322148

Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits.

Wei-Qun Wang1, Chelsea Robertson, Arvinder K Dhalla, Luiz Belardinelli.   

Abstract

Ranolazine [Ranexa; (+/-)-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine] is novel anti-ischemic agent that has been shown to inhibit late I(Na) and I(Kr) and to have antiarrhythmic effects in various preclinical in vitro models. This study was undertaken to investigate the effects of ranolazine on drug-induced Torsade de Pointes (TdP) in vivo. TdP was induced by an I(Kr) blocker, clofilium, in anesthetized, alpha(1)-agonist-sensitized rabbits. Clofilium prolonged QT interval corrected for heart rate (QTc) (52 +/- 9%) and monophasic action potential duration (MAPD)(90) (56 +/- 9%) and caused TdP in eight of eight rabbits. Pretreatment with ranolazine (480 microg/kg/min) or lidocaine (200 microg/kg/min) reduced the clofilium-induced prolongation of QTc (15 +/- 3 and 19 +/- 3%, respectively, p < 0.001 versus vehicle) and MAPD(90) (21 +/- 4 and 20 +/- 2%, respectively, p < 0.001 versus vehicle) and prevented the occurrence of TdP (zero of eight and zero of eight, respectively). Administration of ranolazine after the first episode of TdP terminated TdP and prevented its recurrence (zero of four versus vehicle, four of four). To rule out an alpha(1)-adrenoceptor antagonistic activity of ranolazine, we compared the effects of ranolazine on blood pressure with those of the alpha(1)-antagonist, prazosin. Although prazosin (10 microg/kg/min) markedly shifted the phenylephrine (alpha(1)-agonist) dose-response curve to the right, it did not have any effect on clofilium-induced prolongation of QTc and MAPD(90) (43 +/- 7 and 53 +/- 9%, respectively) or the occurrence of TdP (seven of eight). In contrast, ranolazine completely suppressed TdP but did not cause any shift in the phenylephrine dose-response curve at the highest dose tested (480 microg/kg/min). We conclude that ranolazine antagonizes the ventricular repolarization changes caused by clofilium and suppresses clofilium-induced TdP in rabbits.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18322148     DOI: 10.1124/jpet.108.137729

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  Ranolazine's sweet side--improvement of glycaemic control by the novel mechanism of skeletal muscle microvascular recruitment.

Authors:  Richard L Verrier
Journal:  J Physiol       Date:  2013-10-15       Impact factor: 5.182

2.  Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2.

Authors:  Ashish Parikh; Rajkumar Mantravadi; Dmitry Kozhevnikov; Michael A Roche; Yanping Ye; Laura J Owen; Jose Luis Puglisi; Jonathan J Abramson; Guy Salama
Journal:  Heart Rhythm       Date:  2012-01-11       Impact factor: 6.343

Review 3.  Pharmacological treatment of acquired QT prolongation and torsades de pointes.

Authors:  Simon H L Thomas; Elijah R Behr
Journal:  Br J Clin Pharmacol       Date:  2015-10-26       Impact factor: 4.335

Review 4.  Electrophysiologic basis for the antiarrhythmic actions of ranolazine.

Authors:  Charles Antzelevitch; Alexander Burashnikov; Serge Sicouri; Luiz Belardinelli
Journal:  Heart Rhythm       Date:  2011-03-21       Impact factor: 6.343

Review 5.  Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

6.  Antiarrhythmic effects of the highly selective late sodium channel current blocker GS-458967.

Authors:  Serge Sicouri; Luiz Belardinelli; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2013-03-22       Impact factor: 6.343

7.  Emerging clinical role of ranolazine in the management of angina.

Authors:  David S Vadnais; Nanette K Wenger
Journal:  Ther Clin Risk Manag       Date:  2010-10-21       Impact factor: 2.423

Review 8.  Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.

Authors:  Attila S Farkas; Stanley Nattel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

Review 9.  Ranolazine: a review of its use in chronic stable angina pectoris.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Effects of ranolazine on torsades de pointes tachycardias in a healthy isolated rabbit heart model.

Authors:  Samuel Sossalla; Nora Wallisch; Karl Toischer; Christian Sohns; Dirk Vollmann; Joachim Seegers; Lars Lüthje; Lars S Maier; Markus Zabel
Journal:  Cardiovasc Ther       Date:  2014-08       Impact factor: 3.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.